Abstract: The present invention relates to a HLA-A2 subtype-specific PLK1-derived epitope inducing an antigen-specific T cell immune response to a PLK1 protein. More specifically, a HLA-A2 subtype-specific PLK-1-derived epitope inducing an antigen-specific T cell immune response to a PLK1 protein according to the present invention can provide a CD8+ T cell immune response specific for tumor cells.

Abstract: Provided is a composition for the prevention or treatment of Hutchinson-Gilford Progeria syndrome (HGPS) using gene editing, which contains sgRNA that hybridizes to mRNA encoding progerin, which causes HGPS, and a gene encoding Cas13 protein acting on the same. When introduced into the cell of a subject to be treated and only the mRNA encoding progerin is selectively cut. There is no need for co-prescribing with other therapies and fewer side effects occur than traditional farnesyltransferase inhibitors (FTIs). The efficiency is higher than when treated using homologous recombination (HR) at the DNA level, treatment using composition can be made reversibly, and the composition can be applied specifically compared to targeted treatment using RNAi (RNA interference), and has fewer side effects. Compared to treatment using CRISPR/Cas9, which directly acts on DNA and produces irreversible results, treatment using composition is reversible and selectively cut only mRNA encoding progerin, thereby ensuring safety.

Abstract: The present invention relates to a HLA-A2 subtype-specific PLK1-derived epitope inducing an antigen-specific T cell immune response to a PLK1 protein. More specifically, a HLA-A2 subtype-specific PLK-1-derived epitope inducing an antigen-specific T cell immune response to a PLK1 protein according to the present invention can provide a CD8+ T cell immune response specific for tumor cells.